My ePortfolio Register   

Future for immunotherapies

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.11
Views: 6479
Rating:

Prof Angus Dalgleish - St George’s University, London, UK

The development of ipilimumab has demonstrated that immunotherapies can impact survival, and therapeutic vaccines such as sipuleucel-T (trade name Provenge) and PSA-TRICOM (trade name PROSTVAC) have also been shown to increase patient survival. Prof Angus Dalgleish explains how these treatments work, explains new data which suggest that affective vaccines will soon be developed for lung cancer and talks about trials that have been conducted to investigate the combination of ipilimumab with vaccines. Prof Dalgleish explains that these vaccines do not appear to be overly specific, outlines how this is likely to make them more affordable and discusses his hopes for their successful combination with other cancer therapies.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence